Wednesday, June 10, 2026

Patent intelligence · DE

DE 102006048130

Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil

granted A61K 9/ 00 A IA61K 31/ 48 A IA61K/3148A61K/97061
Status granted
Years to expiry 2
Applicant portfolio 8
Patent details — DE 102006048130
Jurisdiction
DE
Status
granted
Grant date
Apr 10, 2008
Expiration
Apr 5, 2028
CPC classes
A61K 9/ 00 A I, A61K 31/ 48 A I, A61K/3148, A61K/97061
View on Google Patents ↗

Quick answer

DE 102006048130 (Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil) is held by AXXONIS PHARMA AG [DE]. Status: granted. Granted Apr 10, 2008. Expires Apr 5, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 9/ 00 A I, A61K 31/ 48 A I, A61K/3148, A61K/97061, A61P/2500, A61P/2514

More from AXXONIS PHARMA AG [DE]

Related pharmaceutical patents in our USPTO index.

  1. CA 2626142

    SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE

    AXXONIS PHARMA AG [DE] · Expires Sep 18, 2028

    granted
  2. IT MI20070164

    CEROTTO TRANSDERMICO

    AXXONIS PHARMA AG · Expires Nov 1, 2027

    granted
  3. DE 102004006048

    Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie

    NEUROBIOTEC GMBH [DE] · Expires Aug 13, 2025

    expired
  4. DE 10341317

    Mittel zur transdermalen Applikation

    NEUROBIOTEC GMBH [DE] · Expires Mar 26, 2025

    expired
  5. AU 2002363847

    1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE

    AXXONIS PHARMA AG [DE] · Expires Sep 17, 2023

    expired
  6. EP 1311248

    TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS

    NEUROBIOTEC GMBH [DE] · Expires May 16, 2023

    expired
  7. EP 1303278

    KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN

    NEUROBIOTEC GMBH [DE] · Expires Apr 18, 2023

    expired

Frequently asked questions

What is US patent 102006048130?

DE 102006048130 (Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil) is held by AXXONIS PHARMA AG [DE]. Status: granted. Granted Apr 10, 2008. Expires Apr 5, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns DE 102006048130?

AXXONIS PHARMA AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.

When does DE 102006048130 expire?

Our index shows an expiration date of Apr 5, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.